HLB TherapeuticsHLB테라퓨틱스
115450 · KOSDAQ · ₩115450 · HLB테라퓨틱스
₩2,635▼ ₩15 (0.57%)End-of-day · Oct 28, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 6.4% | 14.6% | 18.6% | 13.9% | 19.3% | 11.8% |
| Operating margin | −14.4% | −5.1% | −13.9% | −16.2% | −16.4% | −25.4% |
| Net margin | −28.0% | −13.3% | −41.5% | −4.3% | −23.6% | −39.5% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | −7.4% | +26.6% | +2.2% | +11.7% | +10.4% | — |
| Operating income growth | −161.9% | +53.6% | +12.4% | −10.4% | +29.0% | — |
| Net income growth | −95.3% | +59.5% | −890.1% | +79.7% | +34.0% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −12.2% | −6.0% | −14.3% | −1.7% | −9.6% | −14.5% |
| Return on assets | −10.3% | −4.3% | −11.2% | −1.6% | −6.4% | −9.4% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 30.5% | 31.5% | 20.9% | 17.1% | 46.5% | 45.9% |
| Net debt to equity | 14.8% | 9.1% | 2.6% | −8.4% | 4.6% | −38.0% |
| Current ratio | 77.6% | 284.2% | 169.6% | 186.0% | 136.5% | 199.7% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: HLB Therapeutics / HLB테라퓨틱스 / 115450 / KRX:115450
Source: KRX statistical information